MMP-3
Matrix metalloproteinase-3 (MMP-3) is a stromelysin that degrades a broad spectrum of extracellular matrix (ECM) proteins, including proteoglycans, laminins, fibronectin, vitronectin, and several collagen types[1]. MMP-3 expression is transcriptionally regulated by inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and its induction involves cooperative signaling through syndecan 4 and the MAPK-NF-κB axis in nucleus pulposus cells[2]. Mechanistically, MMP-3 mediates matrix catabolism in intervertebral disc degeneration and contributes to tissue remodeling in chronic inflammatory conditions[2][1]. Compared with related stromelysin isoforms such as MMP-10 and MMP-11, MMP-3 exhibits unique promoter responsiveness to TNF-α via p38 and ERK2 signaling, highlighting isoform-specific regulation[3]. Experimental inhibition of MMP-3 using MAPK or NF-κB pathway inhibitors, or through TGF-β treatment, demonstrates that selective pathway modulation can effectively reduce cytokine-induced MMP-3 expression[2]. These properties make MMP-3 a valuable biomarker and experimental target in studies of disc degeneration, arthritis, and ECM remodeling, while its selective modulation aids in evaluating therapeutic strategies for inflammatory and degenerative diseases[2][1].
References:
- [1]. Wang X, et al. Tumor necrosis factor-α- and interleukin-1β-dependent matrix metalloproteinase-3 expression in nucleus pulposus cells requires cooperative signaling via syndecan 4 and mitogen-activated protein kinase-NF-κB axis: implications in inflammatory disc disease. Am J Pathol. 2014 Sep;184(9):2560-72. [Content Brief]
- [2]. Kunisch E, et al. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis. 2007 Aug;66(8):1043-51. [Content Brief]
- [3]. Díez J. Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. Eur J Clin Invest. 2002 May;32(5):291-4. doi: 10.1046/j.1365-2362.2002.00980.x. PMID: 12027866. et al. Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. Eur J Clin Invest. 2002 May;32(5):291-4. [Content Brief]
-
MMP-3 Related Products (57)
Related Products (57)
-
Recombinant Proteins (2)
-
Antibodies (1)
-
Canine Thrombin
0 ImagesCat. No.: HY-114164FCAS No.: 9002-04-4Canine Thrombin is a Canine serine protease that plays a central role in blood coagulation. Canine Thrombin stimulates macrophages to polarize into a unique phenotype characterized by anti-inflammatory and pro-repair properties. Canine Thrombin activates PAR1, induces the production of MCP-1, MMP3 and VEGF in intervertebral discs, and causes degradation of the cartilage matrix and destruction of intervertebral disc structure. Canine Thrombin activity increases significantly in paraoxon-induced status epilepticus.
-
Mca-P-Cha-G-Nva-HA-Dap(DNP)-NH2
0 ImagesCat. No.: HY-P3098CAS No.: 256394-94-2
-
CGS 27023A free base
0 ImagesCat. No.: HY-18694ACAS No.: 161314-70-1CGS 27023A free base is a non-peptidic and orally active MMP inhibitor with the Ki values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 amd MMP-9, respectively. CGS 27023A free base prevents cartilage degradation in stromelysin-induced rabbit cartilage degradation model. CGS 27023A free base can be used for study of arthritis.
-
CP-544439
0 ImagesCat. No.: HY-107013CAS No.: 230954-09-3CP-544439 is a potent and orally active matrix metalloproteinase-13 (MMP-13) inhibitor with an IC50 of 0.75 nM.
-
CGS 27023A
0 ImagesCat. No.: HY-18694CAS No.: 169799-04-6
-
(Rac)-Tanomastat
0 ImagesCat. No.: HY-12168BCAS No.: 179545-76-7Synonyms: (Rac)-BAY 12-9566(Rac)-Tanomastat ((Rac)-BAY 12-9566) is the racemate of Tanomastat. Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models.
-
NFF-3
0 ImagesCat. No.: HY-P2185CAS No.: 158584-09-9NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity.
-
Berkeleyamide B
0 ImagesCat. No.: HY-N16408CAS No.: 1019854-22-8Berkeleyamide B is a dual matrix metalloproteinase-3 (MMP-3) and caspase-1 inhibitor. Berkeleyamide B is promising for research of cancers and inflammatory disease (e.g., rheumatoid arthritis).
-
Matrix metalloproteinase 3
0 ImagesCat. No.: HY-P3202CAS No.: 79955-99-0Synonyms: MMP-3; Stromelysin-1Matrix metalloproteinase 3 (MMP-3) is a member of the class of zinc-dependent proteases that can degrade the extracellular matrix (ECM). Matrix metalloproteinase 3 palys an important role in the neuronal apoptotic process as well as in neuroinflammation. Matrix metalloproteinase 3 can be used in the study of neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
-
Berkeleyamide C
0 ImagesCat. No.: HY-N16409CAS No.: 1019854-23-9Berkeleyamide C is a selective matrix metalloproteinase-3 (MMP-3) and caspase-1 inhibitor. Berkeleyamide C blocks MMP-3-mediated tumor cell invasion and metastasis, as well as the abnormal activation of inflammation and apoptosis related to caspase-1. Berkeleyamide C is promising for research of cancers and inflammation-related diseases.
-
BIM-46174
0 ImagesCat. No.: HY-183400CAS No.: 195450-11-4BIM-46174 is a heterotrimeric G protein complex inhibitor. BIM-46174 blocks GPCR downstream signaling by trapping Gα proteins in a nucleotide-free pocket conformation, thereby inhibiting Gαq-mediated calcium release, Gαs-mediated cAMP production, and GPCR-regulated cancer cell invasion. In vitro, BIM-46174 effectively suppresses a variety of clinically multidrug-resistant cell lines and induces tumor cell apoptosis through activation of caspase-3 and PARP cleavage. BIM-46174 also inhibits activation of the Neu1-MMP-9-GPCR signaling platform and downstream NF-κB signaling, and is widely used in the study of cancer signaling pathways and inflammation-related research, including lung cancer, pancreatic cancer, breast cancer, melanoma, and leukemia.
-
CM-352
0 ImagesCat. No.: HY-117464CAS No.: 1664361-37-8CM-352 (compound 5) is an inhibitor of matrix metalloproteinases (MMPs) (MMP-3: IC50=15 nM; MMP-10: IC50=12 nM). CM-352 has significant antifibrinolytic activity (EC50=0.7 nM) and can significantly prolong blood coagulation time. CM-352 can be used in anti-bleeding research.
-
Lixisenatide (Leu-13C6,15N) TFA
0 ImagesCat. No.: HY-P0119SLixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
-
MMP3-IN-4
0 ImagesCat. No.: HY-114065CAS No.: 191326-92-8
-
L 696418
0 ImagesCat. No.: HY-187685CAS No.: 147485-09-4L 696418 is a MMP-3 inhibitor with a Ki value of 310 nM. L 696418 inhibits MMP-3 activity, thereby preventing the release of proteoglycans from cartilage. L 696418 reduces proteoglycan release in rabbit knee joints exposed to interleukin-1β (IL-1β). L 696418 can be used in research related to cartilage degradation.
